2023
Dual organ transplantation: when heart alone is not enough
Nuqali A, Bellumkonda L. Dual organ transplantation: when heart alone is not enough. Current Opinion In Organ Transplantation 2023, 28: 370-375. PMID: 37582057, DOI: 10.1097/mot.0000000000001093.Peer-Reviewed Original ResearchConceptsDual-organ transplantationOrgan transplantationPatient selectionBetter long-term outcomesDual organ transplantsSingle organ transplantationTransplant center experienceLong-term outcomesAdvanced disease processLong-term managementPosttransplant outcomesCenter experienceImmunological advantageOrgan transplantsDisease processPartial toleranceSecond organPatientsTransplantationLack of standardizationOutcomesOrgansUrgent needTransplantAssociation of short-term hospital-level outcome metrics with 1-year mortality and recurrence for US Medicare beneficiaries with ischemic stroke
Wang Y, Leifheit E, Goldstein L, Lichtman J. Association of short-term hospital-level outcome metrics with 1-year mortality and recurrence for US Medicare beneficiaries with ischemic stroke. PLOS ONE 2023, 18: e0289790. PMID: 37561680, PMCID: PMC10414659, DOI: 10.1371/journal.pone.0289790.Peer-Reviewed Original ResearchConceptsIschemic strokeInverse probability weightsStroke patientsCause mortalityOutcome metricsLower riskUS hospitalsBetter long-term outcomesRecurrent stroke rateIschemic stroke recurrenceIschemic stroke patientsLong-term outcomesUS Medicare beneficiariesPerformance categoriesIntermediate hospitalsRecurrent strokeStroke recurrenceCohort studyClinical factorsRecurrence ratePrincipal diagnosisPatient riskStroke rateReadmission measuresCox modelPercentage of negative urine drug screens as a clinically meaningful endpoint for RCTs evaluating treatment for cocaine use
Loya J, Babuscio T, Nich C, Alessi S, Rash C, Kiluk B. Percentage of negative urine drug screens as a clinically meaningful endpoint for RCTs evaluating treatment for cocaine use. Drug And Alcohol Dependence 2023, 248: 109947. PMID: 37276806, PMCID: PMC10498479, DOI: 10.1016/j.drugalcdep.2023.109947.Peer-Reviewed Original ResearchConceptsUrine drug screensClinical trialsMeaningful endpointsCocaine useLong-term clinical benefitBetter long-term outcomesDrug screensPsychosocial functioningNegative urine drug screensLong-term outcomesRandomized clinical trialsFuture clinical trialsBetter psychosocial functioningClinical benefitPharmacological treatmentContinuous abstinenceTreatment periodTreatment respondersSustained abstinenceSubstance useTrialsTreatmentMeaningful thresholdPooled datasetAbstinenceCausal Bayesian machine learning to assess treatment effect heterogeneity by dexamethasone dose for patients with COVID-19 and severe hypoxemia
Blette B, Granholm A, Li F, Shankar-Hari M, Lange T, Munch M, Møller M, Perner A, Harhay M. Causal Bayesian machine learning to assess treatment effect heterogeneity by dexamethasone dose for patients with COVID-19 and severe hypoxemia. Scientific Reports 2023, 13: 6570. PMID: 37085591, PMCID: PMC10120498, DOI: 10.1038/s41598-023-33425-3.Peer-Reviewed Original ResearchConceptsCritical COVID-19Better long-term outcomesCOVID-19Entire trial populationStandardized dosing protocolsMultiple patient characteristicsDose of dexamethasoneLong-term outcomesIL-6 inhibitorsDexamethasone doseSevere hypoxemiaMost patientsPatient characteristicsRespiratory supportDiabetes mellitusClinical outcomesDosing protocolTrial populationTreatment effect heterogeneityPatient featuresPatientsAdditional studiesDexamethasoneDoseMore evidenceThe current state-of-the-art in pharmacotherapy for pediatric generalized anxiety disorder
Castagna P, Farahdel E, Potenza M, Crowley M. The current state-of-the-art in pharmacotherapy for pediatric generalized anxiety disorder. Expert Opinion On Pharmacotherapy 2023, 24: 835-847. PMID: 37074259, PMCID: PMC10197951, DOI: 10.1080/14656566.2023.2199921.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsSelective serotonin reuptake inhibitorsSelective norepinephrine reuptake inhibitorGeneralized anxiety disorderAnxiety disordersReuptake inhibitorsPediatric generalized anxiety disorderBetter long-term outcomesSecond-line treatmentNorepinephrine reuptake inhibitorsSerotonin reuptake inhibitorsFirst-line interventionLong-term outcomesCombination of psychotherapyPrevalent psychiatric disordersEvidence-based statePediatric anxiety disordersArt pharmacotherapyModerate effect sizeFunctional outcomeEarly recognitionMood disordersElevated riskPsychiatric disordersBetter outcomesElectronic databasesThe Assessment and Management of Insomnia Among Older Adults
Johnson C, Srinivasan S, Dix E, Tampi R. The Assessment and Management of Insomnia Among Older Adults. American Journal Of Geriatric Psychiatry 2023, 31: s19. DOI: 10.1016/j.jagp.2022.12.301.Peer-Reviewed Original ResearchSleep disordersCognitive behavioral therapyOlder adultsBehavioral therapyREM sleep behavior disorderSimilar short-term outcomesBetter long-term outcomesFirst-line treatmentSleep behavior disorderObstructive sleep apneaNon-pharmacological interventionsShort-term outcomesLong-term outcomesRestless legs syndromeEvaluation of insomniaManagement of insomniaMaintenance of sleepVariety of treatmentsAge-related changesMechanism of actionElderly patientsAdjunctive treatmentLegs syndromeLine treatmentSleep apnea
2022
A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation— part 1: a guide to decision-making
Detterbeck FC, Blasberg JD, Woodard GA, Decker RH, Kumbasar U, Park HS, Mase VJ, Bade BC, Li AX, Brandt WS, Madoff DC. A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation— part 1: a guide to decision-making. Journal Of Thoracic Disease 2022, 0: 0-0. PMID: 35813719, PMCID: PMC9264102, DOI: 10.21037/jtd-21-1823.Peer-Reviewed Original ResearchLong-term outcomesIndividual patientsHealthy patientsLung cancerFavorable tumorsStage I lung cancerBetter long-term outcomesI lung cancerStage I NSCLCOlder patientsPatient selectionPoint of careSurgical approachClinical careEffect modifiersTreatment selectionPatientsTreatment approachesPatient valuesClinical judgmentSystematic reviewRelevant outcomesLong-term differencesAvailable evidenceShort-term differences
2020
Patterns of Transitions Between Relapse to and Remission From Heavy Drinking Over the First Year After Outpatient Alcohol Treatment and Their Relation to Long-Term Outcomes
Maisto SA, Hallgren KA, Roos CR, Swan JE, Witkiewitz K. Patterns of Transitions Between Relapse to and Remission From Heavy Drinking Over the First Year After Outpatient Alcohol Treatment and Their Relation to Long-Term Outcomes. Journal Of Consulting And Clinical Psychology 2020, 88: 1119-1132. PMID: 33370135, PMCID: PMC7900838, DOI: 10.1037/ccp0000615.Peer-Reviewed Original ResearchConceptsLong-term outcomesHeavy drinkingBetter long-term outcomesAlcohol use disorder treatmentRemission/relapsePattern of remissionOutpatient alcohol treatmentUse disorder treatmentFirst yearContinuous relapseContinuous remissionMore relapsesClinical courseOutpatient treatmentRemissionDrinking statusLong-term recoveryRelapsePosttreatment periodDisorder treatmentAlcohol treatmentRelapse episodesAverage durationFunctioning outcomesHeavy drinking statusTreatment Selection and Survival Outcomes in Locally Advanced Proximal Gastric Cancer: A National Cancer Data Base Analysis
Tang S, Liu F, Li Y, Zhao L, Wang X, Khan SA, Chen Y, Zhang Y. Treatment Selection and Survival Outcomes in Locally Advanced Proximal Gastric Cancer: A National Cancer Data Base Analysis. Frontiers In Oncology 2020, 10: 537051. PMID: 33102212, PMCID: PMC7546198, DOI: 10.3389/fonc.2020.537051.Peer-Reviewed Original ResearchBetter long-term outcomesProximal gastrectomyTotal gastrectomyLong-term outcomesPreoperative chemotherapyAdvanced proximal gastric cancer patientsNational Cancer Data Base analysisAdvanced proximal gastric cancerProximal gastric cancer patientsNational Cancer Data BaseCox proportional hazards modelPostoperative chemoradiation therapyProximal gastric cancerUnderwent proximal gastrectomyUnderwent total gastrectomyImproved overall survivalProximal gastric adenocarcinomaGastric cancer patientsProportional hazards modelLong-term survivalEligible patientsPostoperative chemotherapyAdjuvant therapyChemoradiation therapyMultimodality treatmentAssociation Between Thrombolytic Door-to-Needle Time and 1-Year Mortality and Readmission in Patients With Acute Ischemic Stroke
Man S, Xian Y, Holmes D, Matsouaka R, Saver J, Smith E, Bhatt D, Schwamm L, Fonarow G. Association Between Thrombolytic Door-to-Needle Time and 1-Year Mortality and Readmission in Patients With Acute Ischemic Stroke. JAMA 2020, 323: 2170-2184. PMID: 32484532, PMCID: PMC7267850, DOI: 10.1001/jama.2020.5697.Peer-Reviewed Original ResearchConceptsIntravenous tissue plasminogen activatorAcute ischemic strokeTissue plasminogen activatorCause mortalityNeedle timeCause readmissionIschemic strokeLong-term outcomesShorter doorBetter long-term outcomesImproved long-term outcomesPlasminogen activatorRetrospective cohort studyGood functional outcomeGuidelines-StrokeCohort studyHospital arrivalHospital dischargeMedian doorEarly administrationMedian agePrimary outcomeThrombolytic therapyFunctional outcomeReadmission
2019
Management of Banded Gastric Bypasses: Revisional Bariatric Surgery After a Fobi–Capella-Banded Gastric Bypass
Afthinos J, Mukherjee I, Gibbs K. Management of Banded Gastric Bypasses: Revisional Bariatric Surgery After a Fobi–Capella-Banded Gastric Bypass. 2019, 45-49. DOI: 10.1007/978-3-030-28273-8_4.Peer-Reviewed Original ResearchGastric bypassBetter long-term outcomesRevisional bariatric surgeryWeight loss outcomesLong-term outcomesFobi-CapellaBariatric surgerySurgical treatmentPreoperative evaluationBariatric surgeonsOperative techniqueLoss outcomesSilastic ringComplicationsBypassWeight lossGold standardOutcomesObesitySurgeryPrevention of recidivismWidespread useManagementSurgeonsClinical Effectiveness of Direct Oral Anticoagulants vs Warfarin in Older Patients With Atrial Fibrillation and Ischemic Stroke
Xian Y, Xu H, O’Brien E, Shah S, Thomas L, Pencina M, Fonarow G, Olson D, Schwamm L, Bhatt D, Smith E, Hannah D, Maisch L, Lytle B, Peterson E, Hernandez A. Clinical Effectiveness of Direct Oral Anticoagulants vs Warfarin in Older Patients With Atrial Fibrillation and Ischemic Stroke. JAMA Neurology 2019, 76: 1192-1202. PMID: 31329212, PMCID: PMC6647003, DOI: 10.1001/jamaneurol.2019.2099.Peer-Reviewed Original ResearchDirect oral anticoagulantsAcute ischemic strokeMajor adverse cardiovascular eventsAdverse cardiovascular eventsIschemic strokeLong-term outcomesAtrial fibrillationCardiovascular eventsOral anticoagulantsClinical effectivenessHigh riskHealth Stroke Scale scoreBetter long-term outcomesFirst year postdischargeStroke Scale scorePatient-centered outcomesPatient-centered measuresDOAC useGuidelines-StrokeCardiovascular readmissionCause readmissionGastrointestinal bleedingStroke preventionWarfarin prescriptionBaseline characteristicsCALGB (Alliance) 40603: Long-term outcomes (LTOs) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) and bevacizumab (Bev) in triple-negative breast cancer (TNBC).
Sikov W, Polley M, Twohy E, Perou C, Singh B, Berry D, Tolaney S, Somlo G, Port E, Ma C, Kuzma C, Mamounas E, Golshan M, Bellon J, Collyar D, Hahn O, Hudis C, Winer E, Partridge A, Carey L. CALGB (Alliance) 40603: Long-term outcomes (LTOs) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) and bevacizumab (Bev) in triple-negative breast cancer (TNBC). Journal Of Clinical Oncology 2019, 37: 591-591. DOI: 10.1200/jco.2019.37.15_suppl.591.Peer-Reviewed Original ResearchTriple-negative breast cancerLong-term outcomesNeoadjuvant chemotherapyPoor outcomeResidual diseaseUntreated triple-negative breast cancerBetter long-term outcomesClinical stage IIDose-dense ACPretreatment clinical stageWeeks of paclitaxelPathologic complete responseResidual cancer burdenStandard neoadjuvant chemotherapyClinical trial informationBreast/axillaBetter EFSPrimary endpointStandard chemotherapyComplete responseTreatment armsCancer burdenChemotherapy dosesClinical stageTrial armsManagement of Degenerative Spondylolisthesis: Analysis of a Questionnaire Study, Correlation With a National Sample, and Perioperative Outcomes of Treatment Options.
Bovonratwet P, Webb ML, Ondeck NT, Cui JJ, McLynn RP, Kadimcherla P, Kim DH, Grauer JN. Management of Degenerative Spondylolisthesis: Analysis of a Questionnaire Study, Correlation With a National Sample, and Perioperative Outcomes of Treatment Options. The International Journal Of Spine Surgery 2019, 13: 169-177. PMID: 31131217, PMCID: PMC6510177, DOI: 10.14444/6023.Peer-Reviewed Original ResearchInstrumented posterior fusionLumbar degenerative spondylolisthesisLong-term outcomesDegenerative spondylolisthesisPerioperative outcomesPosterior fusionSurgical treatmentSurgical approachPractice patternsSurgical techniqueSurgeons National Surgical Quality Improvement ProgramNational Surgical Quality Improvement ProgramBetter long-term outcomesSurgical Quality Improvement ProgramPerioperative outcome measuresPostoperative adverse eventsACS-NSQIP dataPosterior surgical approachLength of stayCommon surgical treatmentSurgical practice patternsQuality Improvement ProgramConservative treatmentAdverse eventsACS-NSQIPLiver Transplantation for Alcoholic Liver Disease An Update
Godfrey EL, Stribling R, Rana A. Liver Transplantation for Alcoholic Liver Disease An Update. Clinics In Liver Disease 2019, 23: 127-139. PMID: 30454827, DOI: 10.1016/j.cld.2018.09.007.Peer-Reviewed Original ResearchConceptsAlcoholic liver diseaseLiver diseaseAbstinence periodBetter long-term outcomesLiver disease burdenSevere alcoholic hepatitisOverall favorable outcomeLong-term outcomesAlcohol use treatmentUnique health concernsMinimum abstinence periodPosttransplantation riskAlcoholic hepatitisLiver transplantationMetabolic complicationsEarly transplantationDisease burdenFavorable outcomeBetter outcomesHealth concernUse treatmentTransplantationOutcomesDiseaseSelection criteria
2017
Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer
Fujii T, Kogawa T, Dong W, Sahin AA, Moulder S, Litton JK, Tripathy D, Iwamoto T, Hunt KK, Pusztai L, Lim B, Shen Y, Ueno NT. Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer. Annals Of Oncology 2017, 28: 2420-2428. PMID: 28961844, PMCID: PMC5834134, DOI: 10.1093/annonc/mdx397.Peer-Reviewed Original ResearchConceptsHER2-negative primary breast cancerAdjuvant hormonal therapyPrimary breast cancerTriple-negative breast cancerEstrogen receptor positivityHormonal therapyBreast cancerER expressionNeoadjuvant chemotherapyOverall survivalReceptor positivityPathological complete response rateHER2-negative breast cancerStage IIHuman epidermal growth factor 2Better long-term outcomesEpidermal growth factor 2Complete response rateProgesterone receptor expressionLong-term outcomesNegative breast cancerTerms of pCRLogistic regression modelsDefinitive surgeryGrowth factor 2How Much Is Too Much? Patterns of Drinking During Alcohol Treatment and Associations With Post-Treatment Outcomes Across Three Alcohol Clinical Trials.
Witkiewitz K, Roos CR, Pearson MR, Hallgren KA, Maisto SA, Kirouac M, Forcehimes AA, Wilson AD, Robinson CS, McCallion E, Tonigan JS, Heather N. How Much Is Too Much? Patterns of Drinking During Alcohol Treatment and Associations With Post-Treatment Outcomes Across Three Alcohol Clinical Trials. Journal Of Studies On Alcohol And Drugs 2017, 78: 59-69. PMID: 27936365, PMCID: PMC5148751, DOI: 10.15288/jsad.2017.78.59.Peer-Reviewed Original ResearchConceptsBetter long-term outcomesLong-term outcomesPersistent heavy drinkingLow-risk drinkingPatterns of drinkingHeavy drinkingClinical trialsAlcohol treatmentWorse long-term outcomesDrinking patternsWeeks of treatmentRandomized clinical trialsNon-heavy drinkingRepeated-measures latent class analysisLow-risk drinkersAlcohol use disorderPost-treatment outcomesAlcohol clinical trialsAlcohol Treatment TrialNegative long-term outcomesTreatment trialsWorse outcomesSecondary data analysisUse disordersPatients
2015
Pancreaticoduodenectomy for locally advanced colon cancer in hereditary nonpolyposis colorectal cancer
Zhu R, Grisotti G, Salem RR, Khan SA. Pancreaticoduodenectomy for locally advanced colon cancer in hereditary nonpolyposis colorectal cancer. World Journal Of Surgical Oncology 2015, 14: 12. PMID: 26769110, PMCID: PMC4714509, DOI: 10.1186/s12957-015-0755-7.Peer-Reviewed Original ResearchConceptsNonpolyposis colorectal cancerHereditary nonpolyposis colorectal cancerAdvanced colon cancerColorectal cancerColon cancerBetter long-term outcomesMulti-visceral resectionAdvanced colorectal cancerEarly-stage diseaseRare clinical entityLong-term outcomesSpecial surgical considerationsPaucity of dataAdvanced diseaseStage diseaseMultidisciplinary treatmentSubtotal colectomyPartial colectomyCase presentationWeClinical entitySurgical considerationsLynch syndromeCancerColectomyPancreaticoduodenectomyPredictors of Abstinence From Heavy Drinking During Follow-Up in COMBINE.
Gueorguieva R, Wu R, Fucito LM, O'Malley SS. Predictors of Abstinence From Heavy Drinking During Follow-Up in COMBINE. Journal Of Studies On Alcohol And Drugs 2015, 76: 935-41. PMID: 26562602, PMCID: PMC4712662, DOI: 10.15288/jsad.2015.76.935.Peer-Reviewed Original ResearchConceptsLong-term outcomesBetter long-term outcomesBetter clinical outcomesDrinking outcomesHeavy drinking daysLogistic regression analysisStrongest predictorLogistic regression modelsPredictors of abstinenceFair classification accuracyPatient characteristicsClinical outcomesTerm outcomesCombined PharmacotherapiesClinical trialsBaseline predictorsTreatment outcomesTreatment phaseOptimizing outcomesDrinking daysBetter outcomesAlcohol Dependence (COMBINE) StudyBehavioral interventionsHeavy drinkingAlternative interventions
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply